Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. HeXun Biosciences Co's Net Income for the
six
months ended in Jun. 2026 was NT$38.4 Mil. Its Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was NT$75.3 Mil.
HeXun Biosciences Co (ROCO:6986) Net Income Explanation
Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:
HeXun Biosciences Co's Earnings per Share (Diluted) (EPS) for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
EPS is most useful for companies that have:
A predictable business
Consistent accounting methods
And few restructurings
The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
HeXun Biosciences Co Net Income Related Terms
HeXun Biosciences Co Net Income Historical Data
* Premium members only.
The historical data trend for HeXun Biosciences Co's Net Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.
Net Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$75.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeXun Biosciences Co (ROCO:6986) has a Net Income of NT$75.3 Mil as of Jun. 2026. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on HeXun Biosciences Co and its competitors.
Is HeXun Biosciences Co's Net Income too high?
HeXun Biosciences Co's current Net Income is NT$75.3 Mil. Overall, HeXun Biosciences Co has a GF Score™ of 42/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HeXun Biosciences Co's Net Income compare to VRTX and REGN?
HeXun Biosciences Co's Net Income of NT$75.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income for a Biotechnology company?
A good Net Income depends on the Biotechnology industry context. However, Net Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income mean?
A high Net Income can signal that a stock is expensive relative to its fundamentals. Net Income is the total earnings after all operating expenses, interest and taxes. View historical data on HeXun Biosciences Co and its competitors. HeXun Biosciences Co's current Net Income is NT$75.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeXun Biosciences Co stock overvalued right now?
Based on GuruFocus' analysis, HeXun Biosciences Co (ROCO:6986) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$110.22, compared to a current price of NT$40.50 — trading 63.3% below its estimated fair value. The current Net Income is NT$75.3 Mil. HeXun Biosciences Co's overall GF Score™ is 42/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income calculated?
Net Income is calculated from a company's financial statements. For HeXun Biosciences Co (ROCO:6986), the current Net Income is NT$75.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HeXun Biosciences Co (ROCO:6986) Overvalued in 2026?
Based on GuruFocus' analysis, HeXun Biosciences Co stock appears to be undervalued.
The current stock price of NT$40.50 is trading 63.3% below its estimated GF Value™ of NT$110.22.
GuruFocus considers HeXun Biosciences Co to be Significantly Undervalued.
Key valuation signals for ROCO:6986:
Net Income: NT$75.3 Mil
GF Value™: NT$110.22 vs. price of NT$40.50 (63.3% below fair value)
No single metric tells the full story. See the ROCO:6986 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
42GF Score
Get the complete analysis for ROCO:6986
Net Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6986 has been successfully added to your 
